New Biomarker Data Show Lilly's Taltz-Zepbound Combination Triggers Broader Immune Changes Than Taltz Alone

Eli Lilly presented new biomarker data on October 9, 2026 at the 2026 Fall Clinical Dermatology Conference, adding a mechanistic layer to earlier efficacy results from TOGETHER-PsO, a trial testing whether combining the psoriasis drug Taltz (ixekizumab) with the obesity drug Zepbound (tirzepatide) outperforms Taltz alone in people who have both psoriasis and obesity.

The Trial Behind the Data

TOGETHER-PsO is a 52-week, randomized, assessor-blinded Phase 3b trial that enrolled 274 adults with moderate-to-severe plaque psoriasis who also had obesity or overweight plus at least one additional weight-related health condition. Participants had a mean baseline body mass index of 39.2. The trial compared Taltz alone against Taltz plus Zepbound, with diet and physical-activity counseling offered in both arms. Lilly had previously reported that the combination produced superior skin clearance and weight loss compared with Taltz alone at the trial's main analysis point, with those gains reportedly maintained through week 52.

What This New Release Is About

Unlike the earlier efficacy readouts, the October 9 presentation didn't report new skin-clearance or weight-loss percentages. It focused on an exploratory, prespecified analysis of circulating blood proteins and gene expression — a way of measuring what's happening biologically beneath the visible clinical response.

The Numbers

At week 36, the combination arm showed changes in 482 distinct proteins and 467 genes, compared with 140 proteins and just 16 genes in the Taltz-alone arm. Lilly said broader biomarker responses were already visible by week 12, well before the week-36 and week-52 clinical assessments. Part of the additional skin-clearance benefit seen with the combination was statistically linked to changes in a subset of neutrophil-related markers, suggesting the combination affects inflammatory immune activity more broadly than ixekizumab's established IL-17A-blocking mechanism alone would predict.

Why Mechanism Data Matters, and Its Limits

Proteomic and gene-expression data like this can help explain why a combination outperforms a single drug, offering a biological rationale rather than just an observed clinical effect. But Lilly described the analysis as exploratory and said it did not apply statistical correction for multiple comparisons, meaning the findings are descriptive rather than confirmatory. It's also mechanism data, not new efficacy data: it doesn't on its own prove the combination works better, only that it produces more widespread measurable biological change, which is a different (and weaker) kind of evidence.

What's Already Been Reported on Efficacy

Separately from this biomarker release, Lilly has reported that at week 52, the Taltz-plus-Zepbound combination produced complete skin clearance (PASI 100) in considerably more participants than Taltz alone, and that a companion trial in psoriatic arthritis (TOGETHER-PsA) showed a similar pattern on joint-disease measures. Those efficacy findings come from the same overall study program but are a separate analysis from the biomarker data described here.

Regulatory and Safety Context

Zepbound (tirzepatide) is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity; Taltz (ixekizumab) is FDA-approved for plaque psoriasis and psoriatic arthritis. The specific combination of the two drugs studied in TOGETHER-PsO is not itself an FDA-approved regimen — it exists so far only within this clinical trial. Lilly reported that adverse events in the combination arm were generally mild to moderate and consistent with each drug's known safety profile, with no new safety signals identified. Anyone managing both psoriasis and obesity should talk with their physician about currently approved treatment options rather than combining prescription drugs outside a formal treatment plan.

Bottom Line

This release adds biological texture to an already-reported efficacy story rather than introducing a new clinical claim. As with any single company-sponsored analysis, independent replication and eventual peer-reviewed publication will matter for how much weight the scientific community ultimately puts on these specific biomarker findings.